Transitional Cell Carcinoma Active Not Recruiting Phase 2 Trials for Nivolumab (DB09035)

Also known as: Carcinoma, Transitional Cell / Carcinoma transitional cell / Transitional cell carcinoma (morphologic abnormality)

IndicationStatusPhase
DBCOND0031000 (Transitional Cell Carcinoma)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02834013Nivolumab and Ipilimumab in Treating Patients With Rare TumorsTreatment
NCT03219775Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell CarcinomaTreatment